Industry proven study startup process optimization key to selection by CIOReview Magazine
SAN FRANCISCO, March 21, 2017 -- goBalto, Inc., the leading provider of cloud-based clinical study startup solutions, has been selected by CIOReview for the second consecutive time as one of the 20 Most Promising Biotech Technology Solution Providers 2017.
The award selection by honorary industrial experts is based on evaluation of goBalto's specialties in helping pharmaceutical and clinical research organizations (CRO) optimize study startup processes and reduce waste; optimization that supports seamless integration into these companies' eClinical ecosystems, thereby offering the flexibility and robustness needed to accelerate the clinical trials process.
Study Startup (SSU) refers to a series of steps performed before a clinical trial begins. These steps typically include activities such as country selection, pre-study visits, site selection and initiation, regulatory document submission, contract and budget negotiations, and enrolling the first patient. Since each of these steps has multiple components, delays in study timelines are commonplace.
"It's a great honor to include goBalto, in our annual ranking list of 20 Most Promising Biotech Technology Solution Providers 2017," said Jeevan George, Managing Editor of CIOReview. "goBalto is the only company offering a complete end-to-end platform for starting clinical trials, from site identification, feasibility assessment and selection through to activation, with comprehensive metrics to track adherences to timeline and budget."
"We are honored that our technology has been acknowledged among the best solutions in the industry for the second year in a row," said Sujay Jadhav, goBalto's CEO. "The CIOReview Awards' recognition of our solutions for accelerating the end-to-end processes for starting clinical trials supports our continued efforts, and that of our customers and partners, to advance SSU."
With recent multiple enterprise expansions goBalto now services more than two-thirds of the top 25 global pharmas and three of the top five CROs, having the largest industry-proven set of country specific regulatory business process workflows and associated in-depth activation metrics.
"Our growth momentum reflects adoption of our innovative efforts by life science organizations engaged in running trials to mitigate risk, ensure compliance, reduce cycle times, minimize costs, and ultimately enable valuable therapies to get to patients sooner," added Jadhav.